4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Jade Biosciences, Inc. (JBIO) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 55 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, JBIO reported $0M in revenue and ($127M) in net income.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
Interactive charts & full statements →
| Income statement | 2025-12-31 |
|---|---|
| Total Revenue | $0M |
| Operating Income (EBIT) | ($114M) |
| Net Income | ($127M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($43M) | ($35M) | ($27M) | ($28M) | ($23M) |
| Net Income | ($40M) | ($32M) | ($25M) | ($32M) | ($38M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | $350M | $73M |
| Total Liabilities | $17M | $120M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive JBIO viewer.
About TickerBase · Data methodology & sources